Displaying drugs 1 - 25 of 251 in total
Desoxyribonuclease
Desoxyribonuclease is a crystalline enzyme that aids in the digestion of the thymus nucleic acid. The mechanism of action of the enzyme involves the splitting of thymus nucleic acid into fragments approaching the size of tetranucleotides without the release of free phosphoric acid. The enzyme's cofactor is reported to be...
Approved
Matched Synonyms: … Pancreatic dornase ... Bovine pancreatic deoxyribonuclease …
Glycerol phenylbutyrate
Glycerol phenylbutyrate is a nitrogen-binding agent. Chemically, it is a triglyceride in which three molecules of phenylbutyrate are linked to a glycerol backbone. FDA approved on February 1, 2013.
Approved
Secretin porcine
Secretin porcine stimulates pancreatic and gastric secretions to aid in the diagnosis of pancreatic exocrine dysfunction and the diagnosis of gastrinoma.
Approved
Matched Description: … Secretin porcine stimulates pancreatic and gastric secretions to aid in the diagnosis of pancreatic exocrine …
Acetohexamide
A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market.
Approved
Investigational
Withdrawn
Sincalide
Sincalide is a medication given by injection to assist in the diagnosis of gallbladder and pancreas disorders. It is identified as the 8-amino acid C-terminal segment of cholecystokinin and is also known as CCK-8. Naturally occurring cholecystokinin is a gastrointestinal peptide hormone normally essential for stimulating protein and fat digestion...
Approved
Matched Description: … Furthermore, sincalide stimulates the pancreatic secretion of bicarbonate and enzymes. …
Erlotinib
Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR)...
Approved
Investigational
Matched Description: … factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic …
Sodium acetate
Sodium Acetate is chemically designated CH3COONa, a hygroscopic powder very soluble in water. Sodium acetate could be used as additives in food, industry, concrete manufacture, heating pads and in buffer solutions. Medically, sodium acetate is important component as an electrolyte replenisher when given intravenously. It is mainly indicated to correct...
Approved
Investigational
Levocarnitine
Constituent of striated muscle and liver. It is used therapeutically to stimulate gastric and pancreatic secretions and in the treatment of hyperlipoproteinemias.
Approved
Investigational
Matched Description: … It is used therapeutically to stimulate gastric and pancreatic secretions and in the treatment of hyperlipoproteinemias …
Pepsin
Pepsin is a potent enzyme in gastric juice that digests proteins such as those in meat, eggs, seeds, and dairy products .
Studies on gastric digestion from 1820-1840 led to the discovery of pepsin as the substance which, in the presence of stomach acid, causes nutrients including meat or coagulated...
Approved
Experimental
Investigational
Matched Description: … cystic fibrosis, pancreatic cancer, acute and chronic pancreatitis, as well as pancreatic surgery [L2357 ... Pepsin is often used as a replacement enzyme for those with pancreatic insufficiency [L2357]. ... Many causes of pancreatic insufficiency require that enzyme replacement therapy is started, including …
Indium In-111 pentetreotide
Indium In 111 pentetreotide (Octreoscan) has been used in trials studying the diagnostic of SARCOIDOSIS, Solid Tumors, and cushing syndrome.
Approved
Investigational
Matched Categories: … Pancreatic Hormones …
Gliquidone
Gliquidone is a sulfonylurea drug used to treat diabetes mellitus type 2. It is an ATP-dependent K+ (KATP) channel blocker. This block causes a depolarization which leads to activation of voltage-dependent Ca channels and Ca2+ influx, and eventually increases insulin release.
Approved
Investigational
Chymotrypsin
Chymotrypsin (EC 3.4.21.1) is a digestive enzyme that promotes proteolysis, or the breakdown of proteins and polypeptides. It is a serine protease synthesized in the pancreas and is a vital component in the pancreatic juice. Like most proteolytic enzymes, chymotrypsin is activated from its inactive zymogen precursor, chymotrypsinogen, in presence...
Approved
Vet approved
Matched Description: … It is a serine protease synthesized in the pancreas and is a vital component in the pancreatic juice. ... Chymotrypsin is the most abundant pancreatic proteases that represent up to 10-20% of the total protein …
Axitinib
Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation...
Approved
Investigational
Asparaginase Erwinia chrysanthemi
Asparaginase Erwinia chrysanthemi is an asparaginase-specific enzyme derived from Erwinia chrysanthemi used as an anticancer agent. It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death. L-asparaginase was first identified in...
Approved
Investigational
Glimepiride
First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in accordance with progressive...
Approved
Matched Description: … ] as they work by stimulating the release of insulin from the pancreatic beta cells and they are also ... The main effect of SUs is thought to be effective when residual pancreatic β-cells are present,[A177715 ... thought to exert extra-pancreatic effects, such as increasing the insulin-mediated peripheral glucose …
Glucagon
Glucagon is a 29 amino acid hormone used as a diagnostic aid in radiologic exams to temporarily inhibit the movement of the gastrointestinal tract and to treat severe hypoglycemia.[L7634,L7637,L7640,L7643,L8519] Glucagon raises blood sugar through activation of hepatic glucagon receptors, stimulating glycogenolysis and the release of glucose.[L7640,L7643]
Glucagon was granted FDA...
Approved
Matched Categories: … Pancreatic Hormones …
Insulin glulisine
Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the...
Approved
Matched Description: … sugar eventually causes cellular resistance to endogenous insulin, and in the long term, damage to pancreatic ... such as [DB00331], [DB01120], or [DB01261] have been tried, when sufficient damage has been caused to pancreatic …
Matched Categories: … Pancreatic Hormones …
Matched Categories: … Pancreatic Hormones …
Tolazamide
A sulphonylurea hypoglycemic agent with actions and uses similar to those of chlorpropamide.
Approved
Investigational
Chlorpropamide
Chlorpropamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class...
Approved
Investigational
Matched Description: … dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic …
Saxagliptin
Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009.
Approved
Insulin aspart
Insulin aspart is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the...
Approved
Matched Description: … sugar eventually causes cellular resistance to endogenous insulin, and in the long term, damage to pancreatic ... such as [DB00331], [DB01120], or [DB01261] have been tried, when sufficient damage has been caused to pancreatic …
Matched Categories: … Pancreatic Hormones …
Matched Categories: … Pancreatic Hormones …
Linagliptin
Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding . Linagliptin was approved by...
Approved
Alogliptin
Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25, 2013.
Approved
Tolbutamide
Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin...
Approved
Investigational
Matched Description: … dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic …
Belzutifan
Belzutifan is an inhibitor of hypoxia-inducible factor 2α (HIF-2α) used in the treatment of von Hippel-Lindau (VHL) disease-associated cancers. The HIF-2α protein was first identified in the 1990s by researchers at UT Southwestern Medical Center as a key player in the growth of certain cancers. Initially considered to be undruggable,...
Approved
Investigational
Displaying drugs 1 - 25 of 251 in total